Since attaining approval by the Chinese Food and Drug Administration in 2011, icotinib, marketed under the brand name Conmana, has reported to have over a third of the Chinese market share in lung cancer therapies.[1] The US patent application for the preparation of icotinib and icotinib hydrochloride was filed on December 28, 2012 and the patent was granted on July 21, 2015.[2] There are currently no active or recruiting clinical trials for icotinib in the United States.[3] Currently, icotinib is the only marketed drug product from Betta Pharmaceuticals, primarily accounting for the companys $1.289 billion earnings in sales in 2016.[4] Beta Pharma owns the international development and production rights of icotinib outside of China
This mechanism remains less well characterized than the two previous ones and requires further independent validation
Thats why more patients in Miami Beach are exploring a regenerative alternative: PRP therapy
MAPK, Mitogen-activated protein kinase
Product Details: Peptide: IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) Sequence: 83 amino acids Purity: 99% (HPLC verified) Form: Lyophilized powder Quantity: 1mg per vial Storage: Store lyophilized peptide at -4F (-20C)
AOD 9604 is a safe alternative for those who dont want to use HGH or are looking for something with fewer side effects
